| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Klebsiella Infections | 5 | 2020 | 466 | 1.32 | Why? |
| Linezolid | 3 | 2017 | 160 | 0.88 | Why? |
| Giardiasis | 1 | 2020 | 34 | 0.86 | Why? |
| Klebsiella pneumoniae | 6 | 2020 | 658 | 0.85 | Why? |
| Carbapenems | 3 | 2019 | 343 | 0.81 | Why? |
| Cancer Vaccines | 3 | 2018 | 136 | 0.81 | Why? |
| Invasive Fungal Infections | 3 | 2019 | 274 | 0.80 | Why? |
| Soft Tissue Infections | 2 | 2018 | 116 | 0.79 | Why? |
| Anti-Bacterial Agents | 13 | 2021 | 10083 | 0.78 | Why? |
| Pulmonary Surfactants | 1 | 2021 | 128 | 0.76 | Why? |
| Chryseobacterium | 1 | 2017 | 16 | 0.71 | Why? |
| Flavobacteriaceae Infections | 1 | 2017 | 19 | 0.71 | Why? |
| Skin Diseases, Infectious | 1 | 2018 | 77 | 0.65 | Why? |
| Amphotericin B | 1 | 2018 | 256 | 0.63 | Why? |
| Bacterial Infections | 3 | 2019 | 2229 | 0.63 | Why? |
| Hemofiltration | 1 | 2017 | 155 | 0.59 | Why? |
| Melanoma | 5 | 2018 | 1229 | 0.57 | Why? |
| Bacteremia | 4 | 2019 | 1372 | 0.56 | Why? |
| Dendritic Cells | 3 | 2018 | 1330 | 0.56 | Why? |
| Oxazolidinones | 1 | 2013 | 49 | 0.53 | Why? |
| Chromatography, High Pressure Liquid | 2 | 2017 | 669 | 0.51 | Why? |
| Candidiasis | 1 | 2017 | 334 | 0.51 | Why? |
| Antifungal Agents | 3 | 2018 | 1828 | 0.49 | Why? |
| Enterobacteriaceae Infections | 2 | 2018 | 529 | 0.48 | Why? |
| Ozone | 1 | 2020 | 757 | 0.48 | Why? |
| Acetamides | 1 | 2013 | 141 | 0.46 | Why? |
| Stem Cell Transplantation | 1 | 2017 | 531 | 0.45 | Why? |
| Precision Medicine | 1 | 2021 | 1477 | 0.42 | Why? |
| Clostridium Infections | 1 | 2017 | 595 | 0.41 | Why? |
| Dried Blood Spot Testing | 1 | 2013 | 383 | 0.40 | Why? |
| Skin Neoplasms | 3 | 2018 | 1679 | 0.39 | Why? |
| Drug Resistance, Bacterial | 3 | 2018 | 1414 | 0.38 | Why? |
| Pancreatitis | 1 | 2017 | 688 | 0.38 | Why? |
| Liver Transplantation | 3 | 2020 | 2864 | 0.35 | Why? |
| Lymphocytes | 1 | 2020 | 3056 | 0.34 | Why? |
| Immunoglobulins, Intravenous | 1 | 2019 | 2705 | 0.33 | Why? |
| CTLA-4 Antigen | 2 | 2018 | 282 | 0.32 | Why? |
| Cephalosporins | 2 | 2018 | 250 | 0.29 | Why? |
| Pseudomonas Infections | 3 | 2018 | 425 | 0.28 | Why? |
| Administration, Inhalation | 2 | 2021 | 1647 | 0.27 | Why? |
| Adrenal Cortex Hormones | 1 | 2021 | 6537 | 0.26 | Why? |
| Italy | 17 | 2020 | 38444 | 0.26 | Why? |
| Immunoglobulin M | 1 | 2019 | 9091 | 0.22 | Why? |
| Inflammation | 2 | 2021 | 13255 | 0.22 | Why? |
| Pseudomonas aeruginosa | 4 | 2018 | 652 | 0.22 | Why? |
| Metronidazole | 1 | 2020 | 59 | 0.22 | Why? |
| beta-Lactam Resistance | 2 | 2019 | 150 | 0.21 | Why? |
| Carbapenem-Resistant Enterobacteriaceae | 2 | 2020 | 214 | 0.21 | Why? |
| Critical Illness | 5 | 2020 | 17281 | 0.21 | Why? |
| Antiprotozoal Agents | 1 | 2020 | 83 | 0.21 | Why? |
| Skin Diseases, Bacterial | 2 | 2021 | 105 | 0.20 | Why? |
| Peptides, Cyclic | 1 | 2021 | 223 | 0.19 | Why? |
| Teicoplanin | 1 | 2021 | 191 | 0.19 | Why? |
| Phospholipids | 1 | 2021 | 202 | 0.19 | Why? |
| Cell Extracts | 1 | 2018 | 27 | 0.19 | Why? |
| Cross Infection | 3 | 2019 | 8675 | 0.19 | Why? |
| Scedosporium | 1 | 2018 | 9 | 0.19 | Why? |
| Wound Infection | 1 | 2019 | 66 | 0.18 | Why? |
| Actinomycosis | 1 | 2017 | 17 | 0.18 | Why? |
| Off-Label Use | 2 | 2020 | 553 | 0.18 | Why? |
| Biliary Tract | 1 | 2017 | 21 | 0.17 | Why? |
| Echinococcosis, Hepatic | 1 | 2017 | 18 | 0.17 | Why? |
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 1573 | 0.17 | Why? |
| Necrosis | 2 | 2017 | 532 | 0.17 | Why? |
| Dinoprostone | 1 | 2018 | 101 | 0.17 | Why? |
| Penicillanic Acid | 1 | 2017 | 58 | 0.17 | Why? |
| Thoracotomy | 1 | 2017 | 85 | 0.17 | Why? |
| Humans | 56 | 2021 | 930598 | 0.17 | Why? |
| Echinococcosis | 1 | 2017 | 40 | 0.17 | Why? |
| Gram-Positive Bacterial Infections | 1 | 2021 | 323 | 0.16 | Why? |
| Tuberculosis, Miliary | 1 | 2017 | 66 | 0.16 | Why? |
| Iodine | 1 | 2018 | 116 | 0.16 | Why? |
| Pneumonia | 1 | 2017 | 5652 | 0.16 | Why? |
| Mycobacterium bovis | 1 | 2017 | 125 | 0.16 | Why? |
| Proto-Oncogene Proteins B-raf | 1 | 2018 | 179 | 0.16 | Why? |
| Azabicyclo Compounds | 1 | 2017 | 91 | 0.16 | Why? |
| Lung Diseases, Fungal | 1 | 2017 | 167 | 0.16 | Why? |
| Respiratory Tract Infections | 1 | 2017 | 6817 | 0.16 | Why? |
| Candida | 2 | 2017 | 425 | 0.15 | Why? |
| Herpesviridae | 1 | 2017 | 100 | 0.15 | Why? |
| Ceftazidime | 1 | 2017 | 134 | 0.15 | Why? |
| Colorectal Surgery | 1 | 2021 | 394 | 0.15 | Why? |
| Time Factors | 8 | 2021 | 31397 | 0.15 | Why? |
| Acinetobacter Infections | 1 | 2019 | 273 | 0.15 | Why? |
| Superinfection | 1 | 2021 | 459 | 0.15 | Why? |
| Meningitis, Viral | 1 | 2017 | 97 | 0.15 | Why? |
| Acinetobacter baumannii | 1 | 2019 | 378 | 0.15 | Why? |
| Tissue and Organ Harvesting | 1 | 2017 | 146 | 0.15 | Why? |
| Endocarditis | 2 | 2018 | 368 | 0.15 | Why? |
| Calcitonin | 1 | 2017 | 201 | 0.15 | Why? |
| Anti-Infective Agents | 2 | 2017 | 1766 | 0.15 | Why? |
| Pharmacogenetics | 1 | 2017 | 222 | 0.15 | Why? |
| Drug Resistance, Multiple, Bacterial | 3 | 2019 | 1115 | 0.15 | Why? |
| Expert Testimony | 1 | 2019 | 658 | 0.14 | Why? |
| Surgery, Computer-Assisted | 1 | 2017 | 183 | 0.14 | Why? |
| Tumor Necrosis Factor-alpha | 2 | 2018 | 2483 | 0.14 | Why? |
| Treatment Outcome | 12 | 2021 | 51732 | 0.14 | Why? |
| Febrile Neutropenia | 1 | 2017 | 179 | 0.14 | Why? |
| Cardiac Surgical Procedures | 2 | 2019 | 1931 | 0.14 | Why? |
| B7-H1 Antigen | 1 | 2018 | 541 | 0.14 | Why? |
| Immunotherapy | 2 | 2018 | 2421 | 0.14 | Why? |
| Graft vs Host Disease | 1 | 2018 | 501 | 0.13 | Why? |
| Meta-Analysis as Topic | 1 | 2021 | 1289 | 0.13 | Why? |
| Troponin | 1 | 2020 | 1058 | 0.13 | Why? |
| Drug Therapy, Combination | 5 | 2020 | 7268 | 0.13 | Why? |
| Myocardial Ischemia | 1 | 2020 | 781 | 0.13 | Why? |
| Mitral Valve | 1 | 2017 | 342 | 0.13 | Why? |
| Male | 25 | 2020 | 367725 | 0.13 | Why? |
| Aged | 21 | 2020 | 215776 | 0.13 | Why? |
| Terminology as Topic | 1 | 2019 | 546 | 0.13 | Why? |
| Enterovirus | 1 | 2017 | 402 | 0.12 | Why? |
| Heart Valve Diseases | 1 | 2017 | 355 | 0.12 | Why? |
| Drug Stability | 1 | 2013 | 236 | 0.12 | Why? |
| Middle Aged | 22 | 2020 | 270681 | 0.12 | Why? |
| Infusions, Intravenous | 1 | 2017 | 1224 | 0.12 | Why? |
| Antiviral Agents | 5 | 2021 | 41703 | 0.12 | Why? |
| Encephalitis, Viral | 1 | 2017 | 355 | 0.12 | Why? |
| Candidemia | 1 | 2017 | 353 | 0.12 | Why? |
| Endocarditis, Bacterial | 1 | 2017 | 344 | 0.12 | Why? |
| Contrast Media | 1 | 2018 | 1011 | 0.12 | Why? |
| Cell Differentiation | 1 | 2018 | 1338 | 0.11 | Why? |
| Minimally Invasive Surgical Procedures | 1 | 2017 | 663 | 0.11 | Why? |
| Lymphadenopathy | 1 | 2017 | 444 | 0.11 | Why? |
| Intensive Care Units | 10 | 2021 | 29594 | 0.11 | Why? |
| Antibodies, Monoclonal | 2 | 2018 | 8041 | 0.11 | Why? |
| Aged, 80 and over | 11 | 2020 | 88759 | 0.11 | Why? |
| Mycoses | 1 | 2018 | 589 | 0.11 | Why? |
| beta-Lactamases | 1 | 2017 | 759 | 0.11 | Why? |
| Female | 23 | 2020 | 380317 | 0.10 | Why? |
| Donor Selection | 1 | 2017 | 804 | 0.10 | Why? |
| Antimicrobial Stewardship | 1 | 2018 | 931 | 0.10 | Why? |
| Multivariate Analysis | 2 | 2017 | 5440 | 0.10 | Why? |
| Postoperative Complications | 2 | 2019 | 5861 | 0.10 | Why? |
| Uncertainty | 1 | 2020 | 1888 | 0.10 | Why? |
| Autopsy | 1 | 2020 | 3495 | 0.09 | Why? |
| Bacterial Proteins | 1 | 2017 | 1318 | 0.09 | Why? |
| Arthritis, Rheumatoid | 2 | 2017 | 2043 | 0.09 | Why? |
| Cost-Benefit Analysis | 1 | 2018 | 2259 | 0.09 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 1261 | 0.09 | Why? |
| Guidelines as Topic | 1 | 2021 | 2844 | 0.09 | Why? |
| Protein Kinase Inhibitors | 1 | 2018 | 1585 | 0.09 | Why? |
| BCG Vaccine | 1 | 2017 | 1137 | 0.08 | Why? |
| Tuberculosis, Pulmonary | 1 | 2017 | 1171 | 0.08 | Why? |
| Blood Coagulation Disorders | 1 | 2021 | 2040 | 0.08 | Why? |
| Shock, Septic | 1 | 2017 | 1313 | 0.08 | Why? |
| Tuberculosis | 1 | 2003 | 2895 | 0.08 | Why? |
| Plasma | 1 | 2017 | 1809 | 0.08 | Why? |
| Intraabdominal Infections | 2 | 2018 | 90 | 0.08 | Why? |
| Hospital Mortality | 3 | 2020 | 22087 | 0.08 | Why? |
| Linear Models | 1 | 2013 | 1914 | 0.08 | Why? |
| Risk Factors | 8 | 2020 | 71621 | 0.08 | Why? |
| Biological Products | 1 | 2021 | 2331 | 0.08 | Why? |
| Disease Management | 3 | 2019 | 6841 | 0.07 | Why? |
| Drug Monitoring | 1 | 2013 | 1408 | 0.07 | Why? |
| Liver Cirrhosis | 1 | 2017 | 1810 | 0.07 | Why? |
| Limit of Detection | 1 | 2013 | 2698 | 0.07 | Why? |
| Hemorrhage | 1 | 2017 | 3013 | 0.07 | Why? |
| Kaplan-Meier Estimate | 3 | 2019 | 4260 | 0.07 | Why? |
| Registries | 3 | 2020 | 12327 | 0.07 | Why? |
| Randomized Controlled Trials as Topic | 2 | 2021 | 10649 | 0.07 | Why? |
| Myocarditis | 1 | 2020 | 2731 | 0.07 | Why? |
| Adult | 12 | 2020 | 244371 | 0.07 | Why? |
| Hematopoietic Stem Cell Transplantation | 1 | 2018 | 2426 | 0.07 | Why? |
| Angiotensin Receptor Antagonists | 1 | 2020 | 3892 | 0.07 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2017 | 3607 | 0.06 | Why? |
| Vitamin D | 1 | 2018 | 2904 | 0.06 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 5277 | 0.06 | Why? |
| Drug Administration Schedule | 2 | 2021 | 2324 | 0.06 | Why? |
| Bacitracin | 1 | 2021 | 17 | 0.06 | Why? |
| Retrospective Studies | 9 | 2021 | 105322 | 0.06 | Why? |
| Neomycin | 1 | 2021 | 21 | 0.06 | Why? |
| Sepsis | 1 | 2019 | 3517 | 0.06 | Why? |
| Immunosuppressive Agents | 1 | 2020 | 6331 | 0.06 | Why? |
| Cathartics | 1 | 2021 | 41 | 0.06 | Why? |
| Anti-Inflammatory Agents | 1 | 2020 | 6153 | 0.05 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.05 | Why? |
| Risk Assessment | 3 | 2020 | 25439 | 0.05 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.05 | Why? |
| Sternum | 1 | 2019 | 30 | 0.05 | Why? |
| Neoplasms | 2 | 2018 | 17251 | 0.05 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.05 | Why? |
| Heart Failure | 1 | 2020 | 6638 | 0.05 | Why? |
| Survival Rate | 3 | 2018 | 9206 | 0.05 | Why? |
| Oximes | 1 | 2018 | 51 | 0.05 | Why? |
| Nervous System Diseases | 1 | 2017 | 4092 | 0.05 | Why? |
| Hypertension | 1 | 2020 | 8895 | 0.05 | Why? |
| Actinomyces | 1 | 2017 | 14 | 0.05 | Why? |
| Ofloxacin | 1 | 2017 | 23 | 0.05 | Why? |
| Infliximab | 1 | 2003 | 502 | 0.05 | Why? |
| Pyrimidinones | 1 | 2018 | 76 | 0.05 | Why? |
| Therapeutic Equivalency | 1 | 2018 | 64 | 0.05 | Why? |
| Symbiosis | 1 | 2017 | 38 | 0.05 | Why? |
| Acinetobacter | 1 | 2018 | 58 | 0.05 | Why? |
| MAP Kinase Kinase Kinases | 1 | 2018 | 48 | 0.04 | Why? |
| Respiration, Artificial | 2 | 2020 | 22116 | 0.04 | Why? |
| Antibiotic Prophylaxis | 1 | 2021 | 399 | 0.04 | Why? |
| Diabetes Mellitus | 1 | 2020 | 8207 | 0.04 | Why? |
| Cholangiography | 1 | 2017 | 19 | 0.04 | Why? |
| Colectomy | 1 | 2021 | 327 | 0.04 | Why? |
| Coccidioidomycosis | 1 | 2017 | 47 | 0.04 | Why? |
| Echinococcus granulosus | 1 | 2017 | 18 | 0.04 | Why? |
| Gentamicins | 1 | 2017 | 76 | 0.04 | Why? |
| Vancomycin-Resistant Enterococci | 1 | 2018 | 104 | 0.04 | Why? |
| Transplantation, Autologous | 1 | 2018 | 364 | 0.04 | Why? |
| Bacterial Vaccines | 1 | 2018 | 139 | 0.04 | Why? |
| Histoplasmosis | 1 | 2017 | 83 | 0.04 | Why? |
| Stroke | 1 | 2020 | 8839 | 0.04 | Why? |
| Minocycline | 1 | 2017 | 101 | 0.04 | Why? |
| Fever of Unknown Origin | 1 | 2017 | 93 | 0.04 | Why? |
| Cryptococcosis | 1 | 2017 | 97 | 0.04 | Why? |
| Reproducibility of Results | 1 | 2013 | 11304 | 0.04 | Why? |
| Interleukin-2 | 1 | 2018 | 443 | 0.04 | Why? |
| Operative Time | 1 | 2018 | 450 | 0.04 | Why? |
| Echinocandins | 1 | 2017 | 139 | 0.04 | Why? |
| Proportional Hazards Models | 2 | 2019 | 6543 | 0.04 | Why? |
| Pandemics | 5 | 2021 | 389249 | 0.04 | Why? |
| Carcinoma, Transitional Cell | 1 | 2017 | 198 | 0.04 | Why? |
| Surgical Wound Infection | 1 | 2021 | 501 | 0.04 | Why? |
| Prospective Studies | 2 | 2019 | 43301 | 0.04 | Why? |
| Tandem Mass Spectrometry | 1 | 2021 | 1031 | 0.04 | Why? |
| Transplantation, Homologous | 1 | 2018 | 757 | 0.04 | Why? |
| Neoplasm Metastasis | 1 | 2018 | 682 | 0.04 | Why? |
| Clinical Trials, Phase II as Topic | 1 | 2018 | 801 | 0.04 | Why? |
| Colistin | 1 | 2017 | 217 | 0.04 | Why? |
| Follow-Up Studies | 3 | 2018 | 17020 | 0.04 | Why? |
| Patient Outcome Assessment | 1 | 2019 | 707 | 0.04 | Why? |
| RNA, Ribosomal, 16S | 1 | 2017 | 793 | 0.03 | Why? |
| Protective Factors | 1 | 2020 | 1720 | 0.03 | Why? |
| Drug Resistance, Neoplasm | 1 | 2018 | 447 | 0.03 | Why? |
| Enterobacteriaceae | 1 | 2018 | 395 | 0.03 | Why? |
| Databases, Factual | 2 | 2020 | 6248 | 0.03 | Why? |
| Administration, Oral | 1 | 2021 | 2340 | 0.03 | Why? |
| Crohn Disease | 1 | 2003 | 959 | 0.03 | Why? |
| Echocardiography, Transesophageal | 1 | 2017 | 447 | 0.03 | Why? |
| Morbidity | 1 | 2020 | 1426 | 0.03 | Why? |
| Allografts | 1 | 2017 | 761 | 0.03 | Why? |
| Immunotherapy, Adoptive | 1 | 2018 | 524 | 0.03 | Why? |
| Pneumonia, Pneumocystis | 1 | 2017 | 322 | 0.03 | Why? |
| Consensus | 2 | 2019 | 6345 | 0.03 | Why? |
| Disease-Free Survival | 1 | 2018 | 1654 | 0.03 | Why? |
| Imidazoles | 1 | 2018 | 631 | 0.03 | Why? |
| Interleukin-1beta | 1 | 2018 | 992 | 0.03 | Why? |
| Virulence | 1 | 2020 | 2172 | 0.03 | Why? |
| Pyridones | 1 | 2018 | 738 | 0.03 | Why? |
| Hospitalization | 2 | 2020 | 54280 | 0.03 | Why? |
| Pulmonary Aspergillosis | 1 | 2017 | 408 | 0.03 | Why? |
| Public Health | 1 | 2018 | 16359 | 0.03 | Why? |
| Urinary Tract Infections | 1 | 2018 | 534 | 0.03 | Why? |
| Young Adult | 3 | 2018 | 93724 | 0.03 | Why? |
| Methicillin-Resistant Staphylococcus aureus | 1 | 2018 | 711 | 0.03 | Why? |
| Prognosis | 3 | 2020 | 32490 | 0.03 | Why? |
| Preoperative Care | 1 | 2021 | 1515 | 0.03 | Why? |
| Neoplasm Staging | 1 | 2018 | 1999 | 0.03 | Why? |
| Antitubercular Agents | 1 | 2017 | 775 | 0.03 | Why? |
| Urinary Bladder Neoplasms | 1 | 2017 | 614 | 0.03 | Why? |
| Alleles | 1 | 2017 | 1557 | 0.03 | Why? |
| Vasculitis | 1 | 2017 | 691 | 0.03 | Why? |
| Lymph Nodes | 1 | 2017 | 1060 | 0.03 | Why? |
| Comorbidity | 3 | 2021 | 34796 | 0.03 | Why? |
| Europe | 2 | 2018 | 12702 | 0.03 | Why? |
| Escherichia coli | 1 | 2018 | 1547 | 0.03 | Why? |
| Tertiary Care Centers | 2 | 2019 | 8248 | 0.03 | Why? |
| Thorax | 1 | 2020 | 1873 | 0.03 | Why? |
| Graft Rejection | 1 | 2020 | 1766 | 0.02 | Why? |
| Sputum | 1 | 2017 | 1720 | 0.02 | Why? |
| Age Factors | 2 | 2020 | 21039 | 0.02 | Why? |
| Propensity Score | 1 | 2017 | 2690 | 0.02 | Why? |
| Odds Ratio | 1 | 2020 | 5861 | 0.02 | Why? |
| Bronchoalveolar Lavage Fluid | 1 | 2017 | 2309 | 0.02 | Why? |
| Delayed Diagnosis | 1 | 2017 | 1529 | 0.02 | Why? |
| Drug Combinations | 1 | 2017 | 3852 | 0.02 | Why? |
| Recurrence | 1 | 2017 | 3675 | 0.02 | Why? |
| Hydroxychloroquine | 2 | 2021 | 12447 | 0.02 | Why? |
| World Health Organization | 1 | 2020 | 4213 | 0.02 | Why? |
| Cells, Cultured | 1 | 2018 | 5835 | 0.02 | Why? |
| Lopinavir | 1 | 2021 | 4308 | 0.02 | Why? |
| Endothelium, Vascular | 1 | 2017 | 1751 | 0.02 | Why? |
| Lung Diseases | 1 | 2020 | 2361 | 0.02 | Why? |
| Drug Evaluation, Preclinical | 1 | 2018 | 3347 | 0.02 | Why? |
| Tissue and Organ Procurement | 1 | 2017 | 1277 | 0.02 | Why? |
| Incidence | 2 | 2018 | 25622 | 0.02 | Why? |
| Monocytes | 1 | 2018 | 2978 | 0.02 | Why? |
| Biomarkers | 2 | 2020 | 23361 | 0.02 | Why? |
| Renin-Angiotensin System | 1 | 2020 | 3661 | 0.02 | Why? |
| Australia | 1 | 2018 | 6306 | 0.02 | Why? |
| Clinical Decision-Making | 1 | 2018 | 3755 | 0.02 | Why? |
| Transplant Recipients | 1 | 2020 | 4982 | 0.02 | Why? |
| Ambulatory Care | 1 | 2021 | 4947 | 0.02 | Why? |
| Adenosine Monophosphate | 1 | 2021 | 5652 | 0.02 | Why? |
| Alanine | 1 | 2021 | 5687 | 0.02 | Why? |
| Immunocompromised Host | 1 | 2020 | 5150 | 0.02 | Why? |
| Sex Factors | 1 | 2020 | 11014 | 0.02 | Why? |
| Elective Surgical Procedures | 1 | 2021 | 5338 | 0.02 | Why? |
| Antirheumatic Agents | 1 | 2017 | 3023 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2017 | 7220 | 0.01 | Why? |
| Liver | 1 | 2017 | 4007 | 0.01 | Why? |
| Antineoplastic Agents | 1 | 2018 | 3550 | 0.01 | Why? |
| Signal Transduction | 1 | 2018 | 7207 | 0.01 | Why? |
| C-Reactive Protein | 1 | 2017 | 7972 | 0.01 | Why? |
| Coinfection | 1 | 2020 | 6820 | 0.01 | Why? |
| Brain | 1 | 2017 | 5133 | 0.01 | Why? |
| Animals | 2 | 2021 | 78931 | 0.01 | Why? |
| Peptidyl-Dipeptidase A | 1 | 2020 | 9659 | 0.01 | Why? |
| Mutation | 1 | 2018 | 12376 | 0.01 | Why? |
| Cohort Studies | 1 | 2021 | 36005 | 0.01 | Why? |
| Tomography, X-Ray Computed | 1 | 2017 | 25144 | 0.01 | Why? |
| United States | 1 | 2018 | 46150 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2017 | 48226 | 0.01 | Why? |
| Adolescent | 1 | 2018 | 86841 | 0.01 | Why? |